Structure Therapeutics Inc.
GPCR Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$21.55
KIRA · Stoqly’s AI analyst, in plain words
- Structure Therapeutics Inc. lost $141M in fiscal 2025.
- Free cash flow was −$226M in fiscal 2025, — of revenue.
Market cap
$4.7B
P/E
—
Revenue
—
Net income
−$141M
Free cash flow
−$226M
Operating margin
—
Structure Therapeutics Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$141M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Structure Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Structure Therapeutics Inc.
- CIK
- 0001888886
Structure Therapeutics Inc. · GPCR
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | −$51.3M | −$89.6M | −$123M | −$141M |
| Diluted EPS | −$5.51 | −$0.81 | −$0.78 | −$0.80 |
| Cash | ||||
| Cash from operations | −$46.1M | −$79.5M | −$117M | −$222M |
| Capital expenditure | $0.2M | $2.2M | $1.3M | $3.6M |
| Free cash flow | −$46.3M | −$81.7M | −$118M | −$226M |
| Share count change | — | 1,049.8% | 43.3% | 12.5% |
| Debt and strength | ||||
| Cash and short-term investments | $90.8M | $467M | $884M | $1.4B |
| Shareholders' equity | −$115M | $453M | $865M | $1.5B |
| Current ratio | 7.2x | 19.1x | 24.7x | 24.8x |
| Returns and quality | ||||
| Return on equity | — | −53.1% | −18.6% | −11.9% |
| Return on tangible equity | — | −19.8% | −14.2% | −9.3% |
| Altman Z'' | −11.4 | 19.7 | 27.4 | 28.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Structure Therapeutics Inc. · GPCR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $21.55 a share, the company is worth $4.7B.
Source: SEC EDGAR XBRL filings (CIK 0001888886). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.